Hence, GAS6 and pentraxin-3 appear to accurately reflect SLE disease activity changes and could therefore be useful biomarkers to monitor ongoing CVD risk and efficiency of (novel) treatments. The gene discussed is PTX3; the disease is systemic lupus erythematosus.